Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine mechanism study in relapsing multiple sclerosis
2018-004557-24Phase 4Completed
- Sponsor
- Universität Münster
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS), sponsored by Universität Münster. Primary endpoint: Change in T-cell and B-cell receptor repertoires after first treatment course. Started Jun 2019; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-004557-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004557-24.